Contact: info@smarteranalyst.com Analyst Highlights Of Week 02/2015 It’s time once again to take a look at what happened in the past week. The following highlights are compiled from research reports released by leading analyst firms. You can also find full stories on our front page or in the archive sections. Please click on the headline to access the summary. Healthcare ARIAD Pharmaceuticals (NASDAQ:ARIA) J.P. Morgan Comments On Ariad Pharmaceuticals Following Update On Iclusig Trial Design - Kasimov Neutral, $8 PT Conatus Pharmaceuticals (NASDAQ:CNAT) Roth Capital Remains Positive On Conatus Despite Practical Difficulties In ACLF Trial - Arce Buy, ⇩$12 PT Gilead Sciences (NASDAQ:GILD) J.P. Morgan Comments On Gilead Following Acquisition Of Phenex’s Liver-Disease Program - Kasimov Overweight, $117 PT KaloBios Pharmaceuticals (NASDAQ:KBIO) Needham Comments On KaloBios Following Phase 2 KB001-A Trial Results In Cystic Fibrosis - Carr Hold Tonix Pharmaceuticals (NASDAQ:TNXP) Roth Capital Reiterates Buy On Tonix Pharmaceuticals Following FDA Meeting Update - Henry Buy, $10 Galena Biopharma (NASDAQ:GALE) Galena’s Fundamental Thesis Remains Strong, Says Roth Capital - Pantginis Buy, $8 Rockwell Medical (NASDAQ:RMTI) Oppenheimer’s Ling Wang Expects Rockwell Medical Shares To Have Significant Upside - Wang Outperform, $24 BIND Therapeutics (NASDAQ:BIND) UPDATE: Cowen Reiterates Outperform On BIND Therapeutics Following Clinical Updates - Schmidt Outperform Sarepta Therapeutics (NASDAQ:SRPT) UPDATE: We Remain Cautious Near Term On Shares Of Sarepta Therapeutics, Says Canaccord - Walsh Hold, $16 Inovio Pharmaceuticals (NASDAQ:INO) Maxim Maintains Buy On Inovio Following HIV immunotherapy Phase I Data - Kolbert Buy, $20 Halozyme Therapeutics (NASDAQ:HALO) MLV Raises Halozyme Therapeutics Price Target On The Back Of Positive Interim Phase 2 Data - Lee Buy, ⇧$15 Celgene Corporation (NASDAQ:CELG) J.P. Morgan Remains On The Sidelines On Celgene; Waits For Additional Drivers Of Near-Term Upside - Kasimov Neutral, $120 GW Pharmaceuticals (NASDAQ:GWPH) UPDATE: Piper Jaffray Maintains Buy On GW Pharmaceuticals Following Sativex Phase III Results - Schimmer Overweight, $147 Keryx Biopharmaceuticals (NASDAQ:KERX) MLV Sees Increasing Likelihood Of Keryx’s Auryxia Approval; Raises Price Target - Zavoico Buy, ⇧$25 Cempra (NASDAQ:CEMP) We See Significant Upside For Cempra Investors, Says Roth Capital - Arce Buy, $35 Regeneron Pharmaceuticals (NASDAQ:REGN) J.P. Morgan Provides Key Thoughts On Regeneron Heading Into 2015 - Kasimov Neutral, $402 Neuroderm (NASDAQ:NDRM) Oppenheimer Raises Neuroderm Price Target Following ND0612 Phase 2 Update - Felt Outperform, ⇧$18 Agenus (NASDAQ:AGEN) MLV Raises Agenus Price Target Following Multi-Year Partnership Agreement With Incyte - Zavoico Buy, ⇧$9 Vertex Pharmaceuticals (NASDAQ:VRTX) We See Potential For Additional Meaningful Upside In Vertex, Says J.P. Morgan - Kasimov Overweight, $130 Basic materials Pacific Ethanol (NASDAQ:PEIX) Roth Capital Comments On Pacific Ethanol Following Aventine M&A Conference Call - Irwin Buy, $16 Halcon Resources (NYSE:HK) MLV: We See Halcon Resources’ Stock Outperforming As Oil Prices Recover - Mabry Buy, $2.50 Sanchez Energy (NYSE:SN) Canaccord Slashes Sanchez Energy Price Target In Light Of 2015 Capex Cut - Berman Buy, ⇩$20 Technology Nokia Corp (NYSE:NOK) Oppenheimer’s Ittai Kidron Sets Expectations On Nokia Ahead Of 4Q14 Results - Kidron Outperform, $12 PT Micron Technology (NASDAQ:MU) UPDATE: Needham Maintains Strong Buy On Micron Technology Following F1Q15 Results - Gill Buy, $60 PT Sprint Nextel Corp (NYSE:S) Canaccord Comments On Sprint Nextel Following Preliminary Subscriber Results For Q3/F14 - Miller Hold, $5 PT Services J.C Penney Company (NYSE:JCP) Oppenheimer Comments On J.C Penney As Sales Growth Picks Up - Nagel Perform Industrial Goods Ballard Power (NASDAQ:BLDP) Roth Capital Slashes Ballard Power Price Target In Light Of Azure Announcement - Koranda Buy, ⇩$2.50 Ratings System Definitions: Buy: Stock is expected to outperform against the market over next 12 months. Hold: Stock is expected to perform in line with the market over next 12 months. Sell: Stock has more downside risk than upside potential at current prices. Expect shares to underperform the market from current prices. Outperform: Stock is expected to outperform within its industry over next 12 months. Market Perform/Neutral: Stock should perform roughly in line with current market. Neither encourages purchase or sale of these securities at current prices. Underperform: Stock's total return is expected to underperform the industry average over next 12 months. Overweight: Stock is expected to perform better than the broad market over next 12 months. Equalweight: Stock is expected to perform in line with broad market over next 12 months. Underweight: Stock is expected to perform worse than broad market over next 12 months.